Alex Goldberg

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Prospect Capital Corporation (NASDAQ:PSEC) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/06/2014 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Prospect Capital Corporation (NASDAQ:PSEC).

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) a biopharmaceutical company that engages in the development of therapeutic products in the United States closed down in its previous session (-3.50%) on 2,145,765 shares traded after NPS Pharmaceuticals Announced to Report 2013 Financial Results on Tuesday, February 18, 2014. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is currently down (-17.26%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)

Prospect Capital Corporation (NASDAQ:PSEC) a business development company closed down in its previous session (-0.81%) on 4,174,200 shares traded after Prospect Capital announced financial results for second fiscal quarter ended December 31, 2013. Prospect Capital Corporation (NASDAQ:PSEC) is currently down (-5.59%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Prospect Capital Corporation (NASDAQ:PSEC)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com